SynthesisEuropean journal of clinical pharmacology2025
Beta-blockers in acute decompensated heart failure with and without cardiogenic shock: Should we initiate, continue, or withdraw? A systematic review and meta-analysis.
Synthesis in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveto evaluate the impact of beta-blocker (BB) initiation, continuation, and withdrawal on in-hospital mortality in patients with severe acute decompensated heart failure (ADHF), particularly those presenting with cardiogenic shock (CS).
designsystematic review and meta-analysis.
settingcohort studies and randomized controlled trials (RCTs) published through December 31, 2024. PATIENTS OR
participantsadult patients with ADHF and CS.
interventionsparenteral beta-blocker. MAIN VARIABLES OF INTEREST: in-hospital mortality.
resultsSixteen studies (12 cohorts and 4 RCTs) comprising 23,947 patients were included. Among them, 3,215 presented with CS, and 1,246 died. Of the total population, 12,952 received BBs and 10,549 did not. Initiation of BBs in previously untreated patients with CS was not associated with a reduction in mortality (RR: 0.82; 95% CI: 0.64–1.04). Continuation of BBs in patients already receiving them at admission significantly reduced mortality by 49% (RR: 0.51; 95% CI: 0.43–0.61). In contrast, BB withdrawal was not associated with increased mortality risk (RR: 1.92; 95% CI: 0.37–10.09).
conclusionsIn adult patients with ADHF and CS, continuing BB therapy appears to improve survival, while discontinuation may be harmful. Initiation of BBs in previously untreated patients might also offer benefits, although the evidence is inconclusive. These findings highlight the importance of individualized BB strategies in critically ill HF patients, though they should be interpreted with caution due to study heterogeneity.
Indexed as
Identifiers
41402676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.